Core Viewpoint - The report highlights the premium rates of AH shares, with Northeast Electric, Zhejiang Shibao, and Sinopec Oilfield Services leading in premium rates, while CATL, China Merchants Bank, and WuXi AppTec are at the bottom of the list [1][2]. Premium Rate Rankings - The top three AH shares by premium rate are: - Northeast Electric (00042) with a premium rate of 815.25% - Zhejiang Shibao (01057) with a premium rate of 351.07% - Sinopec Oilfield Services (01033) with a premium rate of 303.37% [2] - The bottom three AH shares by premium rate are: - CATL (03750) with a premium rate of -12.99% - China Merchants Bank (03968) with a premium rate of -1.83% - WuXi AppTec (02359) with a premium rate of 3.29% [2] Deviation Values - The top three shares by deviation value are: - Guoen Technology (02768) with a deviation value of 64.57% - Goldwind Technology (02208) with a deviation value of 30.74% - Sinopec Oilfield Services (01033) with a deviation value of 27.72% [1][2] - The bottom three shares by deviation value are: - Junda Co., Ltd. (02865) with a deviation value of -49.44% - Zhejiang Shibao (01057) with a deviation value of -46.76% - Yangtze Optical Fibre and Cable (06869) with a deviation value of -34.58% [1][3].

Core Viewpoint - WuXi AppTec is experiencing growth due to its position as a leading Contract Research Organization (CRO) and its benefits from the depreciation of the Renminbi, with a significant portion of its revenue coming from overseas markets [2][3]. Company Overview - WuXi AppTec is an international leader in providing integrated new drug research and production services for the global biopharmaceutical industry, focusing on small molecule chemical drug discovery, development, and production [2]. - The company has a comprehensive platform service model that caters to global pharmaceutical companies, including medical device testing and precision medical research and production services abroad [2]. - As of September 30, 2025, WuXi AppTec reported a revenue of 32.857 billion yuan, representing a year-on-year growth of 18.61%, and a net profit of 12.076 billion yuan, with an impressive growth of 84.84% [7]. Financial Performance - The company’s overseas revenue accounted for 78.67% of its total revenue, benefiting from the depreciation of the Renminbi [3]. - The main business revenue composition includes chemical business (78.37%), testing business (12.93%), biological business (6.02%), and other services [7]. - WuXi AppTec has distributed a total of 14.06 billion yuan in dividends since its A-share listing, with 10.406 billion yuan distributed over the past three years [8]. Market Activity - On February 4, the stock price of WuXi AppTec increased by 1.07%, with a trading volume of 3.14 billion yuan and a turnover rate of 1.34%, leading to a total market capitalization of 285.277 billion yuan [1]. - The stock has seen a net inflow of 118 million yuan from major investors, indicating a positive sentiment in the market [4][5].

Core Viewpoint - The healthcare sector is experiencing a significant rebound, with the largest healthcare ETF (512170) showing strong performance and attracting substantial capital inflows, indicating renewed investor interest in the sector [1][3][4]. Group 1: ETF Performance - The healthcare ETF (512170) rose over 1.4% after recovering from previous lows, successfully surpassing the 5-day and 60-day moving averages [1]. - The ETF has seen a continuous premium in trading, reflecting active buying interest, with a net inflow of 2.688 billion yuan over the last 12 trading days [3]. Group 2: Earnings Forecasts - As of now, 18 constituent stocks of the healthcare ETF have disclosed their earnings forecasts for 2025, with 11 expected to report profits. Notably, 12 stocks are projected to achieve double-digit growth [4]. - Specific companies like Lepu Medical are forecasting a net profit increase of 224% to 3.86 billion yuan, while other leading CXO firms like Zhaoyan New Drug and Boteng Co. are also expected to see substantial profit growth [4][5]. Group 3: Market Trends - The recovery in the global investment landscape, ongoing domestic support for the innovative drug sector, and a revival in new drug development are contributing to a positive outlook for the CXO industry [4]. - By 2026, structural reforms and improved policy and financing environments are expected to drive the Chinese pharmaceutical industry towards high-quality development [4]. Group 4: ETF Characteristics - The healthcare ETF (512170) is the largest in the market, with a fund size of 27.5 billion yuan, covering over 50% in medical devices and nearly 25% in CXO [6]. - The ETF includes 12 stocks related to AI medical and brain-computer interface concepts, providing a diversified investment opportunity in the healthcare sector [6].

消息面上，近日，由脑机交互与人机共融海河实验室周鹏智慧中医团队牵头，天津中医药大学第一附属 医院、天津市滨海新区中医医院、天津中医药大学、天中依脉公司等多家优势单位联合研发的全国首个 脑控针灸融合神经康复装备平台"神工-华佗"落地。团队创新性研发了"脑机接口+智能穿戴式针灸"融合 技术，相关研究已获国家载人航天实验项目等多项前期项目支撑。 截至2026年2月4日 13:13，中证医药及医疗器械创新指数(931484)成分股方面涨跌互现，东阿阿胶领涨 3.35%，恩华药业上涨1.14%，康弘药业上涨1.03%；特宝生物领跌。医疗创新ETF(516820)最新报价0.36 元。 华金证券认为，政策端持续加码——国家药监局首次将"人工智能医疗器械"列为四大重点发展领域，技 术端DeepSeek-R1等开源大模型显著降低开发门槛，共同推动国内AI+医疗市场进入高速增长通道；全 球AI医疗市场规模预计2022–2030年CAGR达35.5%，至2030年将达1553亿美元。 从资金净流入方面来看，医疗创新ETF近13天获得连续资金净流入，最高单日获得4182.65万元净流 入，合计"吸金"2.46亿元，日均净流入达18 ...

截至2026年2月4日 10:58，中证医药及医疗器械创新指数(931484)成分股方面涨跌互现，东阿阿胶领涨 3.31%，恩华药业上涨1.62%，新和成上涨1.57%；特宝生物领跌。医疗创新ETF(516820)最新报价0.36 元。 从资金净流入方面来看，医疗创新ETF近13天获得连续资金净流入，最高单日获得4182.65万元净流 入，合计"吸金"2.46亿元，日均净流入达1890.95万元。（数据来源：Wind） 消息面上，阿斯利康宣布未来十年在中国投资150亿美元，重点投向细胞治疗与放射性偶联药物 （RDC）两大前沿方向，涵盖北京、上海的战略研发中心建设，以及无锡、泰州、青岛、北京等地生 产基地扩建与新建，并计划将中国高技能员工队伍扩展至超2万人。 风险提示：基金有风险，投资需谨慎。基金管理人承诺以诚实信用、勤勉尽责的原则管理和运用基金资 产，但不保证本基金一定盈利，也不保证最低收益。基金管理人提醒投资人基金投资的"买者自负"原 则，在做出投资决策后，基金运营状况与基金净值变化引致的投资风险，由投资人自行负担。基金的过 往业绩及其净值高低并不预示其未来业绩表现，基金管理人管理的其他基金的业绩不构成对本 ...

Core Viewpoint - The Shanghai 180 Index and its corresponding ETF have shown strong performance, with significant increases in key constituent stocks, indicating a positive market sentiment and potential investment opportunities in the Shanghai securities market [1][2]. Group 1: Index Performance - As of February 3, 2026, the Shanghai 180 Index rose by 1.40%, with notable gains from stocks such as JinkoSolar (up 13.27%) and Sany Heavy Industry (up 7.95%) [1]. - The Shanghai 180 ETF (530280) increased by 1.64%, with a latest price of 1.24 yuan, and has seen a cumulative rise of 1.81% over the past month [1]. - The ETF has a year-to-date maximum drawdown of 4.28%, with a relative benchmark drawdown of 0.06% [1]. Group 2: Liquidity and Trading Data - The Shanghai 180 ETF had a turnover rate of 0.78% during the trading session, with a transaction volume of 458,700 yuan [1]. - The average daily trading volume over the past year for the ETF was 159,160 yuan [1]. Group 3: Fund Metrics - The ETF has a Sharpe ratio of 2.08 since its inception as of January 30, 2026 [1]. - The management fee for the ETF is 0.15%, and the custody fee is 0.05% [1]. - The tracking error for the ETF over the past six months is 0.023% [1]. Group 4: Top Constituent Stocks - The top ten weighted stocks in the Shanghai 180 Index account for 24.85% of the index, with major contributors including Zijin Mining, Kweichow Moutai, and Ping An Insurance [2]. - The individual weightings of these stocks range from 4.22% for Kweichow Moutai to 1.79% for Industrial Fulian [3].

Core Viewpoint - The pharmaceutical sector is experiencing a mixed performance in 2025, with a significant number of companies forecasting profit increases, while others are facing substantial losses. Group 1: Profit Forecasts - A total of 283 pharmaceutical stocks have disclosed their 2025 earnings forecasts, with 160 companies expecting year-on-year profit growth. Among these, Sino Medical has the highest projected increase, with an expected profit growth of over 32 times [1][4]. - WuXi AppTec is anticipated to achieve a record net profit of 19.15 billion yuan, marking the highest since its listing. This includes nearly 5.6 billion yuan in non-recurring gains from the sale of equity interests [6]. - Sino Medical's projected net profit for 2025 is between 43 million and 50 million yuan, reflecting a year-on-year increase of 2,767% to 3,233%. The growth is attributed to stable revenue from its neuro-interventional business and a 22% increase in its coronary intervention business due to the implementation of a national procurement policy [4][5]. Group 2: Loss Forecasts - Over 120 companies are forecasting profit declines for 2025, with 39 facing their first losses since going public, including companies like Zhifei Biological and Zhenbao Island. Zhifei is expected to report a loss of between 10.698 billion and 13.726 billion yuan, a decline of 630% to 780% compared to the previous year [2][8]. - Zhenbao Island anticipates a net loss of between 1.012 billion and 1.173 billion yuan, attributed to delays in the procurement process and increased cost control measures [8]. - Huiyu Pharmaceutical's losses are primarily due to non-core investment losses, with a fair value loss of 173 million yuan from its investment in Zhejiang Tongyuan Kang Pharmaceutical [9]. Group 3: Innovative Drug Companies - The innovative drug sector is showing signs of recovery, with companies like Nocera and Rongchang Biopharma expected to turn losses into profits. Nocera forecasts a net profit of approximately 633 million yuan, a significant increase from the previous year [3][11]. - Rongchang Biopharma is also expected to achieve profitability with projected revenues of around 3.25 billion yuan, a year-on-year increase of about 89% [11]. - Companies like Junshi Biosciences are reducing their losses significantly, with an expected net loss of around 873 million yuan, a reduction of 408 million yuan compared to the previous year [11][12].

Consumer Sector - Major companies are accelerating their C-end AI initiatives, with significant marketing investments exceeding 4.5 billion CNY from Tencent, ByteDance, and Baidu for the Spring Festival[4] - The top three AI applications have achieved over 100 million monthly active users (MAU): Doubao (approximately 320 million), Deepseek (approximately 150 million), and Qianwen (approximately 100 million) as of January 2026[7] High-end Manufacturing - Elon Musk announced plans to build 200 GW of solar capacity in the U.S. within three years, focusing on space-based solar energy, but the short-term impact on the photovoltaic industry remains limited[14] - Major photovoltaic companies are projected to incur significant losses in 2025, with Longi Green Energy, Tongwei Co., and TCL Zhonghuan each expected to lose over 6 billion CNY[17] Hard Technology - The electronic supply chain is experiencing a divergence in performance, with upstream companies like Western Digital and Seagate reporting better-than-expected earnings due to AI-driven demand, while downstream sectors face cost pressures[19] - Global smartphone SoC shipments are expected to decline by 7% in 2026, with low-end models under the most pressure[22] Health Sector - The CXO and research upstream sectors are showing signs of recovery, with notable profit growth expected for leading companies: WuXi AppTec's net profit is projected to increase by 102.65% to 19.15 billion CNY in 2025[26] - Global biopharmaceutical financing data is expected to show a 2.7% increase in 2025, with China's growth rate at 6.4%[28]

Summary of Key Points Core Viewpoint - The A-share market experienced significant block trading activity on February 3, with a total transaction value of 2.236 billion yuan, highlighting notable trading in specific stocks such as Shanghai Airport, Zijin Mining, and Longjing Environmental Protection [1]. Group 1: Block Trading Activity - A total of 80 stocks underwent block trading, with Shanghai Airport leading at 349 million yuan, followed by Zijin Mining at 274 million yuan and Longjing Environmental Protection at 161 million yuan [1]. - Among the stocks traded, 7 were sold at par value, 2 at a premium, and 71 at a discount, indicating a predominance of discounted trades [1]. Group 2: Premium and Discount Rates - The stocks with the highest premium rates were DeMa Technology at 5.67% and Shen High-Speed at 2.01% [1]. - The stocks with the highest discount rates included Kai Fa Technology at 29.94%, New Wave Shares at 23.56%, and Ai Meike at 23.43% [1]. Group 3: Institutional Buying and Selling - The top institutional buying positions included Shanghai Airport at 349 million yuan, Longxin Zhongke at 116 million yuan, and Xinyuan Shares at 60.575 million yuan [2]. - The leading institutional selling positions were Nanxin Technology at 8.4 million yuan and Guobo Electronics at 4.1784 million yuan [2].

截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 無錫藥明康德新藥開發股份有限公司 呈交日期: 2026年2月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02359 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 510,476,909 | RMB | | 1 | RMB | | 510,476,909 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 510,476,909 | RMB | | 1 | RMB | | 510,476,909 | | 2. 股份分類 | 普通股 | A 股份類別 | | | 於香港聯交所上市 (註1) | | 否 ...